OTC-BB:TBPMF

Tetra Bio-Pharma Announces Listing to OTCPink Market

Retrieved on: 
Friday, February 10, 2023
OTC Markets Group, Toronto Stock Exchange, TBP, Disclosure, FRA, Rainbow, Stock, TSX, Security (finance), Financial adviser, Tetra

Existing U.S. shareholders of Tetra will now find common shares quoted on the OTCPink without any further action needed.

Key Points: 
  • Existing U.S. shareholders of Tetra will now find common shares quoted on the OTCPink without any further action needed.
  • The Pink Open Market provides brokers with a regulated platform for transparent trading and best execution.
  • Brokers quote a wide spectrum of companies on this market, including foreign companies that limit their disclosure in the U.S., penny stocks and shells.
  • To be eligible for quotation on the Pink Market, companies must comply with the requirements of Securities Exchange Act Rule 15c2-11, including providing current information to the investing public1.

REDUVO™ Marketing Approval on the Right Path

Retrieved on: 
Thursday, December 22, 2022
Tetra, Patient, Vomiting, Plasma protein binding, NDS, Health Canada, Weight loss, TSX, Insurance, TBP, Dronabinol, FRA, FDA, THC, Inflammation, Safety, Risk management plan, Risk management, HIV/AIDS, News, HIV, Multimedia, Cannabis, CINV, Pain, Nausea, Legislation, Physician, Research, Pharmaceutical industry

The Company will be submitting the response to Health Canada within the allowed timeframe.

Key Points: 
  • The Company will be submitting the response to Health Canada within the allowed timeframe.
  • Questions/feedback from Health Canada are received as the review of the dossier progresses through different review streams.
  • It is also used to treat weight loss and severe nausea in people living with HIV infection.
  • The active pharmaceutical ingredient in REDUVO™ is dronabinol, also known as THC, a synthetic form of the active natural substance in cannabis.

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir

Retrieved on: 
Tuesday, December 6, 2022

Results from the PIONEER clinical trial shows Favipiravir may improve severe COVID-19 recovery and ventilator-free survival in younger patients.

Key Points: 
  • Results from the PIONEER clinical trial shows Favipiravir may improve severe COVID-19 recovery and ventilator-free survival in younger patients.
  • Tetra and Cellvera to develop an orally administered treatment, ARDS-003, in combination with Favipiravir.
  • Guy Chamberland, CEO and Chief Regulatory Officer at Tetra commented "We are very pleased by these artificial intelligence results as well as the recent positive results from the PIONEER trial.
  • PIONEER: A Randomised Controlled Trial of Early Intervention in Patients Hospitalized with COVID-19: Favipiravir verses Hydroxychloroquine & azithromycin & zinc vErsEs Standard CaRe.

Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003

Retrieved on: 
Tuesday, November 29, 2022
IP, FIH, TSX, Multimedia, PCT, United States Patent and Trademark Office, End organ damage, Pain, Safety, Insurance, Physician, Patent Cooperation Treaty, Solubility, Patient, Legislation, Plasma protein binding, Inflammation, Composition, Patent, TBP, News, COVID, Research, HU308, Sepsis, FRA, FDA, Generic drug, Pharmaceutical industry, Tetra

Tetra strengthens its intellectual property position with PCT and provisional patent applications for its innovative therapeutic, ARDS-003.

Key Points: 
  • Tetra strengthens its intellectual property position with PCT and provisional patent applications for its innovative therapeutic, ARDS-003.
  • MONTREAL, Nov. 29, 2022 /PRNewswire/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced the filing of three patent applications for its novel therapeutic, ARDS-003.
  • The Company filed a provisional patent application with the United States Patent and Trademark Office related to crystalline Onternabez and uses thereof.
  • Guy Chamberland, CEO and Chief Regulatory Officer at Tetra commented "This is a significant step in protecting our novel therapeutic, ARDS-003.

Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission

Retrieved on: 
Friday, November 18, 2022
Tetra, Plasma protein binding, Vomiting, TSX, Pain, CINV, NDS, Dronabinol, Cannabis, News, Legislation, Physician, HIV/AIDS, Health Canada, Safety, THC, FDA, Weight loss, HIV, Insurance, Research, Multimedia, Patient, FRA, Inflammation, TBP, Nausea, Pharmaceutical industry

MONTREAL, Nov. 18, 2022 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on the REDUVO New Drug Submission (NDS).

Key Points: 
  • MONTREAL, Nov. 18, 2022 /PRNewswire/ -Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on the REDUVO New Drug Submission (NDS).
  • On December 30, 2020, the Company submitted its first new drug submission ("NDS") for the REDUVO soft gel capsules to Health Canada to obtain approval and a drug identification number ("DIN") for the prescription drug.
  • On November 16, the Company received a Clarification Request (Clarifax) from Health Canada regarding the product labels.
  • The active pharmaceutical ingredient in REDUVO is dronabinol, also known as THC, a synthetic form of the active natural substance in cannabis.

Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean

Retrieved on: 
Thursday, October 27, 2022
Tetra, ABO, Inflammation, Regulation, Funding, Terminology, Sale, Investor, Indian stock exchange, Toronto Stock Exchange, Pain, Insurance, Plasma protein binding, Forward-looking statement, Debenture, FDA, Patient, Company, Compliance, Amendment, Legislation, Person, TBP, TSX, Research, Securities Act of 1933, News, Multimedia, Risk, FRA, View, Warrant, Physician, Safety, Security (finance)

The Debentures issued as part of the second tranche do not bear interest and will mature on October 26, 2023.

Key Points: 
  • The Debentures issued as part of the second tranche do not bear interest and will mature on October 26, 2023.
  • The Warrants issued as part of the second tranche have an expiry date of October 26, 2025.
  • Each closing of a tranche of the Financing is subject to a number of conditions precedent.
  • There is no guarantee that the Company will be able to meet all of the conditions precedent for a particular tranche.

Tetra and Prepaire Jointly Apply to BARDA for Funding

Retrieved on: 
Tuesday, October 11, 2022

Companies jointly submitted a $750,000 USD application to BARDA to use Prepaire Shield discovery platform to assess repurposed drugs combined with onternabez as Chemical Threat Medical Countermeasures.

Key Points: 
  • Companies jointly submitted a $750,000 USD application to BARDA to use Prepaire Shield discovery platform to assess repurposed drugs combined with onternabez as Chemical Threat Medical Countermeasures.
  • Tetra and Prepaire will combine their respective expertise and capabilities to reinvent the drug development process through a fast, innovative, and cost-effective approach using the Prepaire Shield discovery platform and Tetra's proprietary compound, onternabez.
  • Pre-clinical efficacy studies have shown that onternabez has anti-inflammatory and anti-fibrotic properties, decreasing pulmonary and systemic inflammation and ARDS-related drug damage.
  • Prepaire Shield is designed to accelerate the pace of discovery and innovation, including its vast data sets and advanced analytics, enabling faster evidence-based decision-making.

Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections

Retrieved on: 
Wednesday, August 10, 2022
Tetra, FDA, Multimedia, Survival, CAR, Mortality, Inflammation, CEO, Forward-looking statement, Legislation, FIH, CRO, Sepsis, COVID, TSX, Research, Pain, Patient, ACE2, Degenerative disease, Company, TBP, View, McIntosh, Cytokine, Safety, Plasma protein binding, Immunodeficiency, FRA, Virus, Disease, Infection, News, Physician, Breathe Me, Insurance, Severe acute respiratory syndrome coronavirus 2, Animal, Viral encephalitis, Terminology, Pharmaceutical industry, Vaccine

These studies explored the potential of ARDS-003 to increase survival metrics following SARS-CoV-2 infection in the humanized ACE2 mouse model.

Key Points: 
  • These studies explored the potential of ARDS-003 to increase survival metrics following SARS-CoV-2 infection in the humanized ACE2 mouse model.
  • Secondary outcomes evaluated ARDS-003 against an antiviral drug, a clinical standard of care therapeutic used for patients with COVID, in SARS-CoV-2 infected animals.
  • Results indicate that compared to placebo, ARDS-003 dose dependently reduced signs of morbidity and mortality, including respiratory distress.
  • An additional study evaluated in vitro viral infectivity and demonstrated dose dependent inhibition of viral replication.

Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update

Retrieved on: 
Monday, June 6, 2022
NDS, DEL, Company, Insurance, Dronabinol, Research, Nausea, TBP, Drug Identification Number, Food, FRA, Legislation, Forward-looking statement, Weight loss, DIN, News, CEO, Partnership, Cannabis, Pain, Inflammation, Multimedia, Physician, HIV/AIDS, FDA, Health Canada, Patient, Health, TSX, Quality of life, Vomiting, THC, HIV, Plasma protein binding, Terminology, CINV, View, Safety, Pharmaceutical industry, Medical device, Tetra

This represents Tetra's second foreign subsidiary and is in line with the Company's global expansion strategy for QIXLEEF, and other future drug candidates.

Key Points: 
  • This represents Tetra's second foreign subsidiary and is in line with the Company's global expansion strategy for QIXLEEF, and other future drug candidates.
  • The new subsidiary follows the recent announcement of Tetra's partnership with CannvalatePty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
  • Accordingly, TBP-AU will benefit from a 43.5% tax credit on all money spent on clinical trials in Australia.
  • Any company that intends to distribute pharmaceutical drugs in Canada must obtain a DEL as per Health Canada regulatory requirements.

Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting

Retrieved on: 
Tuesday, May 31, 2022
Tetra, Physician, Inflammation, Pain, Company, Environment, Multimedia, Patient, Insurance, SEDAR, View, Health, Meeting, Plasma protein binding, The Meeting, COVID-19, TSX, FDA, TBP, Safety, FRA, Pharmaceutical industry

Please refer to the Company's report of voting results filed under the Company's SEDAR profile at www.sedar.com on May 31, 2022 for further details on the above matters.

Key Points: 
  • Please refer to the Company's report of voting results filed under the Company's SEDAR profile at www.sedar.com on May 31, 2022 for further details on the above matters.
  • This year again, the Company held its Meeting as a virtual only meeting, where all Shareholders regardless of geographic location had an equal opportunity to participate at the Meeting.
  • The virtual-only format for the Meeting also helped to mitigate health and safety risks to the community, shareholders, employees, and other stakeholders in light of the continuing COVID-19 environment.
  • Their evidence-based scientific approach has enabled them to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology.